Paradoxical lucidity in severe end stage dementia: a mixed methods prospective study
严重末期痴呆的矛盾清醒:一项混合方法前瞻性研究
基本信息
- 批准号:10896626
- 负责人:
- 金额:$ 84.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-30 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AdherenceAdverse eventBiologicalBiological MarkersBrainCaregiversCerebral IschemiaCerebrumCessation of lifeCharacteristicsCognitiveConsciousConsentDataDementiaElderlyElectroencephalographyEpidemiologyEventFactor AnalysisFamilyFocus GroupsFrequenciesFutureHeart ArrestImpaired cognitionIncidenceInterventionLife ExpectancyLocationMeasurementMethodsMonitorNatureNear-Death ExperienceNeurobiologyNeurologicNew YorkNursing HomesNursing ServicesPalliative CarePatientsPersonsPhasePreparationProspective StudiesProspective, cohort studyQuestionnairesRecordsReportingResearchResourcesServicesSiteStudy SubjectSurveysSymptomsTestingTherapeuticTimeVisiting Nurseadvanced dementiacognitive functioncostdesigndiariesend of lifehospice environmentinsightmultidisciplinarynovelphenomenological modelspreventprimary outcomerecruitsafety and feasibilitysafety outcomessecondary outcometheoriestool
项目摘要
Project Summary/Abstract
Dementia is expected to impact 75 million people by 2030. It is inevitably considered progressive and irreversible
in nature and culminates into an advanced stage. However, paradoxical episodes of unexpected cognitive
lucidity (paradoxical lucidity [PL]) especially near the end of life have been reported anecdotally for years in
patients with advanced dementia. Although, little is known about PL, yet if confirmed systematically, its
occurrence may challenge current assumptions and highlight the possibility of a network-level return of cognitive
function. This may provide novel insights into the underlying neurobiology and delineate future therapeutic
possibilities. While, there is no definition of PL, and no systematic studies have assessed the epidemiology,
neurologic underpinnings, and phenomenology of PL in dementia, however, lucidity and/or consciousness with
phenomenological similarities to PL have been described during other brain states which are also not expected
to support lucidity. This includes severe cerebral ischemia in cardiac arrest (CA) (at times referred to as near-
death experiences [NDE]). Some data suggests these lucid death related episodes may correlate with surges in
electrocortical activity, which may in turn provide mechanistic insights and biological plausibility for PL in severe
dementia. We have pioneered research into NDE’s and found a similar phenomenology to PL in severe
dementia. Our team has conducted largescale multisite studies, including a current 20-site study of NDE’s in
1500 CA subjects with real-time biomarkers of electrocortical activity using electroencephalography (EEG). We
are proposing to test the hypothesis that patients with advanced end stage dementia with an estimated life
expectancy 7 days can be successfully identified and recruited into a study exploring episodes of PL at the end
of life. Furthermore, we hypothesize that the use of symptom diaries and video, audio and EEG monitoring will
be feasible and deemed not sufficiently intrusive to prevent its use for patients or their families at the end of life
in a larger prospective study.Through a multidisciplinary team, including the Visiting Nurse Service of New York’s
(VNSNY) hospice services we aim to systematically study the phenomenology, characteristics, and
electrocortical biomarkers of PL in dementia and create a measurement scale.The R21 phase aims are 1) To
obtain necessary and sufficient data to determine the safety and feasibility of using symptom diaries and real-
time video EEG monitoring for a future study of PL in advanced dementia 2) To obtain necessary and sufficient
data to design a prospective cohort study of PL in advanced dementia and its underlying cerebral electrocortical
biomarkers The R33 phase aims are to 3) Conduct a mixed methods prospective study of PL during end stage
advanced dementia 4) Create a definition and measurement scale for PL in advanced dementia and to 5) Explore
the potential electrocortical biomarkers of PL in advanced dementia.
项目概要/摘要
预计到 2030 年,痴呆症将影响 7500 万人。它不可避免地被认为是进行性且不可逆转的
然而,意想不到的认知的矛盾事件。
清醒(矛盾的清醒[PL]),尤其是在生命即将结束时,多年来一直有轶事报道。
尽管人们对 PL 知之甚少,但如果得到系统证实,它是有可能的。
事件的发生可能会挑战当前的假设,并凸显网络层面认知回归的可能性
这可能为潜在的神经生物学提供新的见解并描绘未来的治疗方法。
虽然 PL 没有定义,也没有系统研究评估流行病学,
然而,清醒和/或意识与痴呆症的 PL 的神经学基础和现象学有关
在其他大脑状态中也描述了与 PL 的现象学相似性,但这也是意料之外的
以支持清醒,这包括心脏骤停 (CA) 中的严重脑缺血(有时称为近乎缺血)。
一些数据表明,这些清醒的死亡相关事件可能与死亡经历的激增有关。
电皮层活动,这反过来可能为严重的 PL 提供机制见解和生物学合理性
我们率先对濒死体验进行了研究,并发现了与严重失智症类似的现象。
我们的团队进行了大规模的多地点研究,包括目前对濒死体验的 20 个地点的研究。
使用脑电图 (EEG) 对 1500 名 CA 受试者进行皮层电活动的实时生物标记。
提议检验以下假设:晚期痴呆症患者的预计寿命
预期 7 天可以成功识别并招募到最后探索 PL 发作的研究中
此外,我们追求使用症状日记和视频、音频和脑电图监测。
可行且被认为没有足够的侵入性来阻止其在生命结束时对患者或其家人的使用
在一项更大规模的前瞻性研究中。通过多学科团队,包括纽约的访问护士服务
(VNSNY)临终关怀服务,我们的目标是系统地研究现象学、特征和
痴呆症 PL 的电皮层生物标志物并创建测量量表。R21 阶段的目标是 1)
获得必要且充分的数据以确定使用症状日记和真实情况的安全性和可行性
时间视频脑电图监测,用于未来晚期痴呆 PL 的研究 2) 获得必要和充分的信息
用于设计晚期痴呆症 PL 及其潜在脑电皮质的前瞻性队列研究的数据
R33 阶段的目标是 3) 在末期对 PL 进行混合方法前瞻性研究
晚期痴呆 4) 创建晚期痴呆 PL 的定义和测量量表,并 5) 探索
晚期痴呆症中 PL 的潜在电皮层生物标志物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sam Parnia其他文献
Sam Parnia的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sam Parnia', 18)}}的其他基金
Neuroprotection following cardiac arrest: A Randomized Control Trial of Magnesium
心脏骤停后的神经保护:镁的随机对照试验
- 批准号:
10742460 - 财政年份:2023
- 资助金额:
$ 84.75万 - 项目类别:
Goal directed cardiopulmonary resuscitation in cardiac arrest using a novel physiological target: A pilot mechanistic randomized control trial
使用新型生理目标进行心脏骤停的目标导向心肺复苏:一项试点机械随机对照试验
- 批准号:
10698018 - 财政年份:2020
- 资助金额:
$ 84.75万 - 项目类别:
Goal directed cardiopulmonary resuscitation in cardiac arrest using a novel physiological target: A pilot mechanistic randomized control trial
使用新型生理目标进行心脏骤停的目标导向心肺复苏:一项试点机械随机对照试验
- 批准号:
10471231 - 财政年份:2020
- 资助金额:
$ 84.75万 - 项目类别:
Paradoxical lucidity in severe end stage dementia: a mixed methods prospective study
严重末期痴呆的矛盾清醒:一项混合方法前瞻性研究
- 批准号:
10095286 - 财政年份:2020
- 资助金额:
$ 84.75万 - 项目类别:
Goal directed cardiopulmonary resuscitation in cardiac arrest using a novel physiological target: A pilot mechanistic randomized control trial
使用新型生理目标进行心脏骤停的目标导向心肺复苏:一项试点机械随机对照试验
- 批准号:
10228545 - 财政年份:2020
- 资助金额:
$ 84.75万 - 项目类别:
相似国自然基金
基于机器学习和影像学多参数融合的心血管不良事件风险预测模型研究
- 批准号:82370513
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
GNB3联合光谱CT冠周脂肪组学预警ACS后心血管不良事件的模型构建
- 批准号:82302186
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于人工智能和多模态信息预测复杂下肢动脉病变术后不良事件的算法机制研究
- 批准号:82370499
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于效用错位视角的医疗不良事件管理政策的引导体系优化研究
- 批准号:72304012
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于真实世界数据的药物相互作用相关不良事件风险评估及其管理策略研究
- 批准号:72304010
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Transovarial transmission of yersinia pestis in fleas
跳蚤中鼠疫耶尔森氏菌的跨卵巢传播
- 批准号:
10727534 - 财政年份:2023
- 资助金额:
$ 84.75万 - 项目类别:
Dose Flexible Combination 3D-Printed Delivery Systems for Antiviral Therapy in Children
用于儿童抗病毒治疗的剂量灵活组合 3D 打印输送系统
- 批准号:
10682185 - 财政年份:2023
- 资助金额:
$ 84.75万 - 项目类别:
Safety and efficacy of Belatacept in heart transplantation
贝拉西普在心脏移植中的安全性和有效性
- 批准号:
10622240 - 财政年份:2023
- 资助金额:
$ 84.75万 - 项目类别:
Targeting Senescence to Improve Frailty in Older Cancer Survivors
瞄准衰老以改善老年癌症幸存者的虚弱状况
- 批准号:
10866293 - 财政年份:2023
- 资助金额:
$ 84.75万 - 项目类别:
A Phase II Randomized Placebo Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Physical Frailty and Tumor Necrosis Factor-alpha and Associated Immune Markers in Older Cancer Survivors
表没食子儿茶素-3-没食子酸酯 (EGCG) 对老年癌症幸存者身体虚弱和肿瘤坏死因子-α 及相关免疫标志物的 II 期随机安慰剂对照试验
- 批准号:
10570438 - 财政年份:2023
- 资助金额:
$ 84.75万 - 项目类别: